News Owlstone's breath diagnostic to be used in asthma research Owlstone's ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
News Owlstone's breath-based lung cancer diagnostic could save 10... Trial's next phase will recruit 3,000 patients across 21 international sites.
News Novo puts $285m into monthly GLP-1 based on Ascendis tech Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.
